DoD Breast Cancer, Breakthrough Award Levels 1 and 2
ID: 354866Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354866
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jun 11, 2024, 12:00 AM UTC
  4. 4
    Due Sep 26, 2024, 12:00 AM UTC
Description

The Department of the Army, through the Congressionally Directed Medical Research Programs (CDMRP), is offering the FY24 Breast Cancer Breakthrough Award Levels 1 and 2 to support innovative research aimed at making significant advancements in breast cancer treatment and prevention. This grant opportunity encourages high-risk, high-reward projects that can lead to breakthroughs in understanding cancer mechanisms and improving health outcomes, particularly for military personnel and the general public. With an estimated total program funding of $12.6 million, the program anticipates awarding approximately eight grants, with funding limits of up to $750,000 for Level 1 and up to $1.5 million for Level 2 applications. Interested applicants must submit a pre-application by September 26, 2024, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.

Point(s) of Contact
help@eBRAP.org
Files
Title
Posted
HT942524BCRPBTA122-GG.pdf
Aug 24, 2024, 2:22 AM UTC
The Department of Defense (DOD) announces the FY24 Breast Cancer Breakthrough Award Levels 1 and 2 through the Congressionally Directed Medical Research Programs (CDMRP), aiming to accelerate high-impact research in breast cancer. The program, which has appropriated $150 million for FY24, encourages innovative projects that address significant challenges in breast cancer, such as prevention, understanding cancer mechanisms, and improving treatment strategies. Eligible applicants include various organizations, both domestic and international, and any investigator may serve as Principal Investigator. A two-step application process involves a pre-application and full application, with specific funding limits for each award level: Level 1 (up to $750,000 for partnering PIs) and Level 2 (up to $1.5 million). Applications are evaluated based on impact, feasibility, personnel qualifications, and innovation, and must align with strategic research goals. Final awards will be granted by September 30, 2025, based on the availability of funds and application merit. This program exemplifies the government’s commitment to advancing cancer research and improving health outcomes for military personnel and the general public.
Similar Opportunities
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
Tactical Behaviors for Autonomous Maneuver
Dept of the Army -- Materiel Command
The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
Airman Readiness Medical Research (ARMR) Hybrid BAA
Air Force -- Research Lab
The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Department of Defense Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)
Dept of the Army -- Materiel Command
The Department of the Army's Materiel Command is offering a federal grant opportunity through the Department of Defense Research and Education Program aimed at Historically Black Colleges and Universities and Minority-Serving Institutions (HBCUs/MIs). This initiative seeks to enhance defense-related research and educational capabilities at these institutions, with a focus on increasing the number of graduates in STEM disciplines and fostering collaborations with other educational institutions and defense organizations. The program is critical for addressing national defense research priorities and strengthening the defense workforce through educational enhancements. Eligible applicants can apply for grants ranging from $100 million, with applications due by July 31, 2029. For further inquiries, interested parties can contact William A. Creech at william.a.creech3.civ@army.mil or by phone at 919-549-4387.
Department of Defense HIV/AIDS Prevention Program
Dept. of the Army -- USAMRAA
The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.